Moderna shares rose by over 4% on a mixed Tuesday for US equities ahead of the US Federal Reserve's rate cut decision today.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Recent CDC data show that that wastewater SARS-CoV-2 detections are high and that LP.8.1 and related strains XFG and NB.1.8.1 ...

CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which ...

丙酸血症是一种罕见的“中毒型”有机酸血症。在日本，通过筛查发现的PA发病率约为每45,000名活产婴儿中就有1例。它具有多系统并发症，包括神经系统表现、心肌病、心律失常、生长迟缓、复发性胰腺炎、骨髓抑制和对感染的高度易感性。其特征是反复发生的、危及生命的代谢失代偿事件（MDEs），MDEs是导致死亡率和长期不可逆神经认知缺陷的主要因素。目前的治疗方法不能解决根本的酶缺陷，主要包括饮食蛋白质限制以减 ...

Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna MRNA and Merck MRK announced new data for individualized neoantigen therapy mRNA-4157 on Monday at the annual meeting of the American Society of Clinical Oncology that was consistent with our ...

Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across ...